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 Abstract
Epilepsy is one of the most common neurologic disorders. The epileptic seizures as well as antiepileptic drugs 
may disturb the reproductive system function. Polycystic ovary syndrome occurs more commonly in women with 
epilepsy, either treated or not with valproic acid. This article discusses the current knowledge about the relationships 
between epilepsy and polycystic ovary syndrome. 
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 Streszcznie
Padaczka jest jedną z najczęstszych chorób neurologicznych. Zarówno napady padaczkowe, jak i stosowane w 
tej chorobie leki mogą zaburzać czynność układu rozrodczego. Zespół wielotorbielowatych jajników występuje 
częściej zarówno u nieleczonych, jak i leczonych kwasem walproinowym kobiet z padaczką. Artykuł przedstawia 
aktualny stan wiedzy na temat związków pomiędzy oboma schorzeniami.
 Słowa kluczowe: zespół wielotorbielowartych jajników (PCOS) / padaczka / 
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Polycystic	ovary	syndrome	(PCOS)	is	a	complex	endocrine	
disorder.	According	to	different	authors,	it	affects	5-10%	of	pre-
menopausal	women	[1].	The	Rotterdam	criteria	suggest	that	PCOS	
is	recognized	when	two	of	the	following	conditions	are	fulfilled: 
1.	menstrual	disorders	or	amenorrhea	with	chronic	lack	of	ovulation, 
2.	 clinical	 and/or	 biochemical	 features	 of	 hyperandrogenism,	
3.	presence	of	the	characteristic	features	of	the	ovaries	in	ultra-
sonography	(polycystic	ovaries	 -	PCO).	Other	diseases	such	as	
congenital	 adrenal	 hyperplasia,	 Cushing	 syndrome,	 androgen-
secreting	tumors,	hyperprolactinemia	and	thyroid	disease	should	
also	be	ruled	out	[1].
Epilepsy
Epilepsy	is	the	most	common	neurological	disease	among	peo-
ple	of	all	ages,	including	women	of	reproductive	age.	By	definition,	
it	is	characterized	by	recurrent	(two	or	more)	epileptic	seizures	that	
are	not	provoked	by	any	factor	[2].	The	incidence	of	epilepsy	in	Eu-
rope,	according	to	an	Italian	study,	is	estimated	as	2,7-3,3/1000	[2]. 
Many	studies	have	shown	an	increased	coincidence	of	epilepsy	
and	polycystic	ovary	 syndrome.	Herzog	has	 shown	 that	PCOS	
occurs	 in	 10-25%	 of	 women	with	 temporal	 epilepsy,	 while	 in	
normal	population	it	is	observed	in	5-10%	[3,	4].	It	is	not	clear	
whether	epilepsy	itself	favors	the	occurrence	of	PCOS,	or	if	there	
is	an	association	between	PCOS	and	antiepileptic	drugs,	particu-
larly	valproic	acid	(VPA).	One	theory	says	that	seizures	can	affect	
the	hypothalamic-pituitary-ovarian	axis	[3,	5].	It	is	suggested	that	
seizures	 throughout	 the	middle	 temporal	area	(medial	 temporal	
areas)	stimulate	the	secretion	of	GnRH	(gonadotropin-releasing	
hormone),	 and	by	 changing	 the	 frequency	of	GnRH	pulses	 in-
crease	the	secretion	of	luteinizing	hormone	(LH),	resulting	in	in-
creased	LH/FSH	ratio	(FSH	–	follicle-stimulating	hormone),	as	
it	is	seen	in	PCOS.	Herzog	and	colleagues	studied	the	frequency	
of	LH	pulses	in	women	with	epilepsy	and	found	that	it	is	higher,	
especially	in	the	left	temporal	lobe	epilepsy	[3,	6,	7].	
Neuroendocrine	disorders	(inappropriately	low	levels	of	FSH	
with	normal	or	increased	concentrations	of	LH)	would	cause	lack	
of	ovulation	and	the	formation	of	immature	ovarian	follicles	that	
produce	testosterone,	but	with	a	deficit	of	aromatase,	the	enzyme	
which	converts	androgens	into	estrogens	[3].	In	addition,	the	in-
creased	level	of	LH	would	affect	the	increased	androgen	produc-
tion	in	ovarian	thecal	cells	[3,	8,	9].
Some	authors	suggest	a	connection	between	location	of	epi-
leptic	foci	and	the	appearance	of	PCOS	features.	Foci	located	in	
the	 left	 temporal	 lobe	would	be	 associated	with	PCOS,	 and	 in	
the	right	temporal	lobe	with	the	occurrence	of	hypogonadotropic	
hypogonadism	 [3].	Other	 researchers	 postulate	 the	 relationship	
between	the	type	of	seizure	with	the	emergence	of	PCOS.	Gener-
alized	seizures	are	associated	with	the	more	frequent	occurrence	
of	menstrual	disorders	and	PCOS.	In	the	study	of	Morrell	et	al.,	
PCO	image	on	ultrasound	was	found	in	41%	of	women	with	gen-
eralized	epilepsy,	and	in	26%	of	women	with	partial	seizures	[5,	
7,	10].	Results	of	other	studies,	however,	did	not	confirm	these	
observations	[7,9].	
Scharfman	et	al.,	in	an	animal	model,	confirmed	the	hypoth-
esis	 that	not	only	drugs	used	for	 treatment	also	but	epilepsy	it-
self	affect	the	appearance	of	features	of	PCOS	in	the	ovary.	They	
showed	that	female	rats	with	pilocarpine-induced	temporal	lobe	
epilepsy,	had	higher	 testosterone	 levels,	 increased	body	weight	
and	more	cysts	seen	on	the	ultrasonography	of	ovaries	in	com-
parison	to	rats	in	the	control	group	[11].
Epilepsy	is	often	associated	with	weight	gain,	and	this	usu-
ally	 affects	women.	Drugs	 used	 for	 treatment	 of	 epilepsy	may	
have	major	influence	on	this	phenomenon.	There	is	no	data	as-
sessing	 the	 impact	of	untreated	epilepsy	on	energy	metabolism	
in	humans	in	the	existing	literature.	But	in	an	animal	model	in-
creased	body	weight	was	observed	in	female	rats	with	epilepsy	
induced	by	lithium	and	pilocarpine	[11].
The	fact	that	increased	incidence	of	PCOS	was	demonstrated	
in	patients	treated	for	epilepsy	with	VPA	may	prove	an	existing	
relationship	between	epilepsy	and	PCOS.	In	teenagers	with	mi-
graine	who	were	treated	with	VPA	or	placebo,	there	were	no	dif-
ferences	in	the	prevalence	of	menstrual	disorders	and	no	increase	
in	testosterone	levels	in	any	of	the	groups	[12].	These	results	may	
indicate	that	epilepsy	and	bipolar	disorder	are	conducive	to	the	
development	of	PCOS	and	the	use	of	VPA	is	an	additional,	but	
not	the	sole	pathogenetic	factor.
Antiepileptic drugs
Antiepileptic	drugs	may	affect	levels	of	biologically	active	
sex	hormones.	Many	of	them	have	long	been	used	in	the	treat-
ment	 of	 epilepsy.	Drugs	 such	 as	 carbamazepine,	 phenobarbital	
or	 phenytoin	 increase	 the	 activity	 of	 hepatic	 cytochrome	P450	
involved	 in	 steroid	 hormone	metabolism	 and	 increase	 the	 pro-
duction	of	 sex	hormone	binding	globulin	 (SHBG),	 resulting	 in	
the	reduction	of	biologically	active	hormone	level	[10].	Reduced	
incidence	of	PCOS	in	women	treated	with	carbamazepine,	com-
pared	to	women	who	were	not	treated,	was	observed	(13	and	30%	
respectively)	[3].	Some	other	drugs,	such	as	valproic	acid,	have	
the	opposite	effect:	they	inhibit	hepatic	enzymes,	which	results	in	
significantly	increased	level	of	biologically	active	sex	hormones,	
including	androgens	[9].
A	 common	 adverse	 effect	 of	 some	 antiepileptic	 drugs	 is	
weight	gain.	These	drugs	include	valproic	acid,	carbamazepine,	
gabapentin	and	vigabatrin.	Increased	body	weight	augments	in-
sulin	resistance	and	 in	women	with	genetic	predisposition	may	
favor	the	occurrence	of	PCOS	[13].
Most	data	on	the	relationship	between	PCOS	and	antiepilep-
tic	drugs	concern	valproic	acid.	Valproic	acid	(VPA)	and	its	me-
tabolites	are	common	antiepileptic	drugs	used	for	both	general-
ized	and	partial	seizures,	as	well	as	in	other	disorders	such	as	bi-
polar	disorder,	migraine,	or	chronic	neuropathic	pain.	Long-term	
treatment	with	VPA	in	women	of	reproductive	age	is	associated	
with	a	higher	incidence	of	polycystic	ovaries	in	ultrasonography,	
hyperandrogenemia,	weight	 gain,	 hyperinsulinemia	 and	 insulin	
resistance	[13].
VPA	 is	a	 short-chain	 fatty	acid,	which	acts	 throughout	 the	
GABA-ergic	 (GABA	 γ-aminobutyric	 acid)	 and	 sodium	 chan-
nel	activity.	Its	impact	on	cell	function	is	also	being	postulated.	
VPA	modulates	 intracellular	 signaling	 systems	 such	 as	MAPK	
(mitogen-activated	protein	kinases),	PCK	(Protein	kinase	C),	Akt	
/	PBK	(The	serine	/	 threonine	protein	kinase	GDP	Also	known	
as	the	Act)	[14].	Chronic	treatment	with	VPA	affects	the	activity	
of	 transcription	 factors.	VPA	 reversibly	 inhibits	 the	 activity	 of	
histone	deacetylases	class	 I	and	consequently	 increases	histone	
acetylation,	which	alters	the	expression	of	selected	genes	[15].
Nelson	DeGrave	et	 al.,	 studied	 the	 effect	of	various	doses	
of	VPA	on	steroidogenic	enzymes	activity	in	thecal	cell	cultures	
obtained	 after	 hysterectomy	 from	women	with	 normal	 ovaries	
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and	 PCOS	 [8].	 VPA	 in	 pharmacological	 doses	 (500uM)	 was	
found	to	increase	synthesis	of	androgens	(dehydroepiandroster-
one	 and	 androstenedione)	 in	 ovarian	 thecal	 cells	 by	 increasing	
gene	expression	of	CYP17	and	CYP11	α.	In	subsequent	studies,	
the	same	authors	showed	that	the	use	of	VPA	caused	changes	in	
gene	expression	in	normal	thecal	cells,	similar	to	those	observed	
in	PCOS	[8,14].
One	of	the	most	common	side	effects	of	VPA	is	weight	gain.	
It	was	observed	in	approximately	43.6%	of	women	and	23.5%	of	
men	on	the	 long-term	VPA	treatment	[13].	There	 is	no	relation	
between	the	dose	and	the	degree	of	weight	gain.	Usually	weight	
gain	is	observed	during	the	first	three	months	of	treatment,	with	
a	maximum	in	the	sixth	month	of	therapy.	It	is	noted	more	fre-
quently	in	patients	who	started	treatment	during	puberty	or	just	
after	puberty.	No	relationship	between	weight	gain	and	the	type	
of	seizures	was	found	but	 there	was	an	association	with	higher	
body	weight	at	the	beginning	of	treatment	[13].
The	precise	pathogenetic	background	of	the	weight	gain	in-
duced	by	administration	of	VPA	is	still	unknown.	It	is	postulated	
that	several	mechanisms	can	be	involved	[13]:
1) Impact on the hypothalamus
Patients	receiving	VPA	showed	an	increase	in	appetite,	thirst	
and	desire	for	high-energy	drinks.	Similar	feelings	can	be	induced	
by	activation	of	the	hypothalamus.	It	was	proved	that	VPA	may	
interfere	 with	 the	 hypothalamic-pituitary-gonadal	 axis	 through	
the	influence	on	GnRH	pulse	generator	[16].
2) Induction of hyperleptinemia and resistance to leptin
Increased	 level	 of	 leptin	 was	 observed	 in	 patients	 taking	
VPA,	but	only	in	those	who	suffer	from	obesity.	It	seems	that	the	
increase	in	leptin	levels	is	associated	with	weight	gain,	and	not	
with	the	direct	influence	of	VPA	on	the	leptin	metabolism	[13].	
This	 is	 supported	by	 several	 facts.	First,	 slim	patients	who	are	
taking	VPA	do	not	show	elevated	levels	of	leptin.	Secondly,	there	
is	no	 significant	difference	 in	 levels	of	 leptin	 in	obese	patients	
taking	VPA	and	in	the	obese	control	group.	Thirdly,	in	a	group	
of	 obese	patients	 treated	with	VPA,	women	have	higher	 leptin	
levels	than	men,	which	corresponds	to	similar	proportions	of	pa-
tients	with	obesity.	The	results	of	some	studies	have	not	shown	
the	influence	of	VPA	on	leptin	levels,	or	some	were	even	counter-
productive.	Lagace	et	al.,	showed	that	VPA	in	a	dose-dependent	
manner	decreased	the	level	of	leptin	mRNA	in	adipocytes,	thus	
significantly	reducing	the	secretion	of	the	hormone	[17].
3) Effects on adiponectin
It	was	shown	that	 the	use	of	VPA	is	associated	with	lower	
levels	of	adiponectin,	but	only	in	people	who	experienced	weight	
gain	 during	 the	 treatment.	 These	 changes	 resemble	 those	 ob-
served	in	adiponectin	levels	in	simple	obesity.	In	addition,	Qiao	
and	colleagues	showed	that	VPA	decreases	adiponectin	gene	ex-
pression	in	mature	adipocytes	by	inhibition	of	histone	deacety-
lase	activity	[18].
4) Insulin resistance and hyperinsulinemia
Isojärvi	et	al.	showed	in	1996	that	women	who	gained	weight	
during	VPA	therapy	had	elevated	levels	of	insulin	[19].	Luef	et	
al.	confirmed	in	2002	that	patients	taking	VPA	had	a	statistically	
higher	BMI	and	higher	postprandial	 insulin	levels	compared	to	
the	 control	group.	 In	 addition,	higher	 concentrations	of	 insulin	
was	also	observed	after	glucose	load	[20].	In	another	study	Pyl-
vänen	and	colleagues	have	shown	that	both	lean	and	obese	indi-
viduals	using	VPA	had	elevated	 insulin	 levels	 [21].	The	use	of	
VPA	is	associated	with	 increased	fasting	 insulin	 levels,	but	not	
with	increased	levels	of	proinsulin	and	C-peptide	in	the	fasting	
state,	suggesting	that	the	drug	has	no	effect	on	insulin	secretion,	
but	only	affects	 the	metabolism	of	 insulin	 in	 the	 liver,	 increas-
ing	the	concentration	of	the	hormone	in	the	periphery	[22].	The	
exact	mechanisms	by	which	VPA	induces	insulin	resistance	and	
hyperinsulinemia	are	not	yet	known.	It	is	suggested	that	VPA	as	
a	 short-chain	 fatty	acid,	competes	with	other	 fatty	acids	 (FFAs	
-	free	fatty	acids)	for	binding	to	insulin,	thus	increasing	their	lo-
cal	availability,	which	contributes	to	the	development	of	insulin	
resistance.	Elevated	levels	of	FFAs	impair	insulin	synthesis	and	
increase	the	proinsulin	/	insulin	ratio	[23].	
Influence	of	VPA	on	reducing	the	activity	of	GLUT1	(Glu-
cose	 transporter	1)	and	direct	effect	of	VPA	on	pancreatic	beta	
cells	is	also	being	considered	[24].	It	was	observed	that	addition	
of	VPA	to	the	pancreatic	beta	cells	cultures	increased	concentra-
tion	of	insulin	in	a	time-	and	dose-	dependent	manner	[25].
5) Genetic factors
Klein	et	al.	observed	five	pairs	of	monozygotic	twins	treated	
with	VPA.	In	all	the	twins	effect	of	VPA	on	the	change	in	body	
weight	 was	 the	 same.	 In	 four	 pairs	 of	 twins	 weight	 gain	 was	
observed,	while	 in	 the	fifth	pair	of	 twins,	body	weight	has	not	
changed.	This	seems	to	confirm	that	genetic	factors	may	play	a	
significant	role	in	the	development	of	obesity	in	humans	treated	
with	VPA	[26].
Polycystic	ovary	syndrome	is	 the	most	common	endocrine	
disorder	in	reproductive	women.	On	the	other	hand,	epilepsy	is	
one	of	the	most	common	neurological	diseases.	Doctors	involved	
in	the	treatment	of	epilepsy	should	not	forget	about	the	possibil-
ity	of	coexistence	of	PCOS	and	its	long-term	consequences	that	
require	careful	observation	and	proper	treatment.
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